Jecure Therapeutics

What Jecure Therapeutics does

Jecure Therapeutics is a privately-held, for-profit biotechnology company headquartered in San Diego, California, founded in 2016. The firm is focused exclusively on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH), a chronic liver disease with high unmet medical need and a competitive therapeutic landscape. The company operates with a small team of 11-50 employees, consistent with an early-stage drug discovery profile.

Jecure's business activity centers on early-stage R&D in the metabolic liver disease space, targeting novel mechanisms relevant to NASH pathogenesis. As a preclinical-stage biotech, the company has raised a $20 million Series A financing round in January 2017 led by Versant Ventures, which would have been deployed toward medicinal chemistry, target validation, and IND-enabling work. No commercial products, licensing deals, partnerships, or revenue-generating collaborations are disclosed in the source material, indicating the company has been operating in a purely investment-funded discovery mode.

Jecure serves the broader biopharmaceutical market indirectly through the development of NASH therapeutic candidates intended for eventual out-licensing, partnership, or acquisition by larger pharma players. The firm has no direct end customers, no pricing model, no go-to-market sales motion, and no disclosed commercial revenue streams; the only documented external counterparty is its lead investor, Versant Ventures.

Name

Jecure Therapeutics

Legal name

Vsport胜利因您更精彩

Website

https://jecuretx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Jecure Therapeutics is a San Diego-based private biotech founded in 2016 that discovers therapeutics for non-alcoholic steatohepatitis (NASH), operating as a preclinical-stage drug discovery company with a $20M Series A led by Versant Ventures.

Ownership category

akta.pro rank

Product category

NASH therapeutics drug discovery

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• NASH therapeutics
• Metabolic liver disease
• Drug discovery
• Small molecule therapeutics
• Preclinical biotechnology

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Research Project Funding: Government-funded research projects including National Natural Science Foundation projects, Hunan Province key research projects, and other provincial/ministerial level funding. In recent 3 years, total research funding exceeded 14 million RMB.
2. Technology Transfer and Consulting Services: Transfer of research achievements including forest fire monitoring systems and remote sensing analysis platforms to government agencies like the Hunan Provincial Forest Fire Prevention Command Center. Also provides GIS and remote sensing technical training services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH). The company conducts early-stage, preclinical research to identify and validate small-molecule drug candidates targeting metabolic liver disease pathways, with the goal of advancing these candidates toward pharmaceutical partnerships and clinical development.

Product overview

Based on the source data, this is an academic department (Vsport/胜利因您更精彩) at Central South University of Forestry and Technology, not a product company. The website describes an educational institution offering undergraduate programs in Geographic Information Science, Surveying Engineering, Remote Sensing Science and Technology, and Artificial Intelligence, as well as master's programs in Remote Sensing Science and Technology and Electronic Information (Artificial Intelligence). There are no commercial products or services described.

Differentiator

Problem solved

Functional benefit

Products and services

• Preclinical NASH therapeutic candidates Preclinical small-molecule drug candidates under discovery and optimization for the treatment of non-alcoholic steatohepatitis and related metabolic liver diseases. Intended to be out-licensed or partnered with large pharmaceutical companies for further clinical development and commercialization.

Quantifiable outcome

• Forest fire monitoring system deployed at provincial level in Hunan, being promoted nationwide
• +4 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Anhui Tianlintai Technology Co., Ltd.coreStrategic or Co-development Partner · 1 January 2015Established industry-academia-research cooperation agreement in 2015. Jointly established polar-orbiting and geostationary meteorological satellite ground stations. The company serves as a production-education base for undergraduate talent training.
• Hunan Second Surveying and Mapping InstituteminorStrategic or Co-development PartnerResearch exchange and collaboration in remote sensing technology applications. The institute serves as a reference for industry practices and provides potential employment opportunities for graduates.
• Hunan Province First and Third Surveying and Mapping InstituteminorStrategic or Co-development PartnerIndustry-academia-research collaboration for student internship and employment opportunities. Provides platform for expanding employment channels for graduates.
• Huatec (华测导航)coreStrategic or Co-development PartnerConducts teaching practical training on campus. Collaborates on UAV aerial survey technology demonstrations and technical discussions. Supports the college's practical teaching transformation.
• South Surveying Group (南方测绘集团)minorStrategic or Co-development PartnerConducts campus recruitment activities. Provides employment opportunities for graduates in surveying and mapping industry.
• Guangtong Surveying CompanyminorChannel Partner/ Reseller/ DistributorConducts campus recruitment activities, hiring graduates for surveying positions.
• China Radio and Television Hunan Network Co., Ltd.minorStrategic or Co-development PartnerCorporate visit and business exchange in July 2025. Explored cooperation opportunities in low-altitude economy, talent joint training, and collaborative scientific research.
• China Broadcasting Hunan Future Digital Technology BranchminorStrategic or Co-development PartnerDiscussed cooperation in subtropical forest and grass digital twin innovation center platform construction.
• Central South University (地球科学与信息物理学院)minorStrategic or Co-development PartnerResearch exchange on talent training program revision. Learning experiences in innovative talent cultivation, curriculum system construction, and intelligent teaching.

Scale indicators12 records

Recent moves2 records

Expansion highlights3 records

Emerging players

• Akero Therapeutics: Clinical-stage developer of FGF21 analogs for NASH/MASH; comparable as a venture-backed hepatology-focused biotech.
• Viking Therapeutics: Mid-stage clinical biotech pursuing metabolic disease therapies including NASH; comparable in clinical stage and therapeutic area overlap.
• Metsera: Emerging obesity/metabolic disease biotech with liver disease overlap; comparable as a discovery-stage peer tackling cardiometabolic indications adjacent to NASH.

Direct peers

• Intercept Pharmaceuticals: Pioneer in NASH/liver disease therapeutics (obeticholic acid); directly comparable as a focused hepatology drug developer targeting NASH fibrosis.
• NGM Biopharmaceuticals: Clinical-stage biotech with NASH and metabolic liver disease programs; small-cap hepatology-focused peer comparable in size and disease focus.
• Madrigal Pharmaceuticals: Developer of resmetirom, an approved NASH/MASH therapy; a direct competitor pursuing innovative therapeutics in the same NASH indication.
• Galmed Pharmaceuticals: Clinical-stage company developing therapeutics for liver, metabolic and inflammatory diseases including NASH, directly comparable in early/small-cap profile.

Broad incumbents

• Gilead Sciences (NASH efforts): Large pharma with significant NASH investment (e.g., simtuzumab, cilofexor programs); comparable as a major competitor in the same therapeutic area, with broader portfolio.
• Pfizer (NASH efforts): Large pharma with active NASH/MASH programs through partnerships and internal candidates; comparable as a deep-pocketed incumbent in the same indication.
• Novo Nordisk (NASH efforts): Global leader in metabolic disease with growing NASH franchise via GLP-1-based combinations; comparable as an incumbent whose diabetes/obesity drugs are directly reshaping the NASH treatment paradigm.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/jecure-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jecure Therapeutics